on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagenic Therapeutics Faces Nasdaq Non-Compliance Notice
Protagenic Therapeutics, Inc. has received a notification from Nasdaq Listing Qualifications Staff. The company is not complying with Nasdaq Listing Rules 5550(b)(1) and 5250(c)(1). The reported stockholders' equity falls below the $2.5 million minimum, and there is a delay in filing the Form 10-Q for the quarter ended September 30, 2025.
The company plans to file the Form 10-Q soon. Under Rule 5815, Nasdaq has determined to delist the company's securities. Protagenic Therapeutics will request a hearing before a Nasdaq Hearings Panel. Filing the request stays any suspension for 15 days.
The company's stock will continue trading during the stay. There is no assurance the Panel will grant an extended stay or additional compliance time. Protagenic intends to present its plan to address deficiencies at the hearing.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news